23 participants with a diagnosis of mild-to-moderate probable AD according to National Institute of Neurologic and Communicative Disorder and Stroke-Alzheimer 's Disease and Related Disorders criteria were randomized into the experimental ( modafinil 200 mg daily ) or control ( placebo ) groups .
